Diagnostic and individualized treatment of localized prostate cancer;Diagnostik und individualisierte Therapie des lokoregionaren Prostatakarzinoms

Urologe - Ausgabe A

Volumn 39, Issue 6, 2000, Pages 578-588

  Wirth, M ^a   Frohner M ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER STAGING; CRYOTHERAPY; DIAGNOSTIC PROCEDURE; HUMAN; INDIVIDUALIZATION; MALE; PROSTATE CANCER; PROSTATECTOMY; REVIEW; TREATMENT PLANNING;

AGED; COMBINED MODALITY THERAPY; DIAGNOSTIC IMAGING; HUMANS; MALE; NEOPLASM STAGING; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0033724645     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001200050415     Document Type: Review

References (61)

1. Treatment of prostate cancer with transrectal focussed ultrasound: First clinical experiences
2. Local control of prostate cancer with HIFU: Preliminary results of french multicentric study
3. The impact of co-moridity on life expactancy among men with localized prostate cancer
4. Long-term survival and mortality in prostate cancer treated with non-curative intent
5. Decrease in prostate cancer mortality following introduction of prostate specific antigen (PSA) screening in the federal state of Tyrol, Austria
6. Three-dimensional computer-simulated prostate models: Lateral prostate biopsies increase the detection rate of prostate cancer
7. Prostate-specific antigen: Current status
8. Contemporary results of anatomic radical prostatectomy
9. Potency, continence, and complication rates in 1.870 consecutive radical retropubic prostatectomies
10. Serious co-morbidity among unselected cancer patients newly diagnosed in the Southeastern part of The Netherlands in 1993-1996
11. Systematic sextant biopsies improve preoperative predition of pelvic lymph node metastases in patients with clinically localized prostatic carcinoma
12. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
13. Management of prostate and bladder cancer in the elderly
14. Comorbid survival among elderly participants of the Canada Health Survey: Relevance to prostate cancer screening and treatment
15. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up
16. Systematic S region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate
17. Neoadjuvant hormone therapy before radical prostatectomy: Update on the Memorial Sloan-Kettering Cancer Center trials
18. Clinical significance of the determination of noncomplexed prostate-specific antigen as a marker for prostate carcinoma
19. Resuits of radical prostatectomy in men with locally advanced prostate cancer: Multi-institutional pooled analysis
20. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: A matched comparison
21. Cancer statistics, 2000
22. Use of second treatment following definitive local therapy for prostate cancer: Data from the caPSURE database
23. Radical perineal prostatectomy: Oncological outcome during a 20-year period
24. High 10-year survival rate in patients with early, untreated prostatic cancer
25. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer
26. Screening decreases prostate cancer death: First analysis of the 1988 Quebec prospective randomized controlled trial
27. Population-based stuy of long-term survival in patients with clinically localised prostate cancer
28. Clinical value of prostate-specific antigen-detected prostate carcinoma (stage T1c)
29. Is systematic sextant biopsy suitable for the detection of clinically significant prostate cancer?
30. Prostate cancer in the elderly
31. Clinical significance of the echogenicity in prostatic ultrasound findings in the detection of prostatic carcinoma
32. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer
33. Radical prostatectomy for carcinoma in men more than 69 years old
34. National patterns of prostate cancer treatment by radical prostatectomy: Results of a survey by the American College of Surgeons Commission on Cancer
35. Radical perineal prostatectomy without pelvic lymphadenectomy: Selection criteria and early results
36. Combination of prostate-specific antigen, clinical stage and Gleason score to predict pathologic stage of localized prostate cancer. A multi-institutional update
37. Comorbidity in patients with prostate cancer and its relevance to treatment choice
38. Natural history of progression after PSA elevation following radical prostatectomy
39. Clinical stage, prostate-specific antigen and Gleason grade to predict extracapsular disease or nodal metastasis in men with newly diagnosed, previously untreated prostate cancer. A multicenter study
40. Retrospective comparison of radical prostatectomy and 125Iodine brachytherapy for localized prostate cancer
41. Evaluation of the digital rectal examination as a screening test for prostate cancer
42. Should patients with very high serum PSA levels (>50 ng/ml) undergo radical prostatectomy?
43. The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results program
44. American Cancer Society guidelines for the early detection of cancer
45. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate
46. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer
47. Perineural invasion and seminal vesicle involvement predict lymph node metastasis in men with localized carcinoma of the prostate
48. Neoadjuvant hormonal therapy improves the outcomes of patients undergoing radioactive seed implantation for localized prostate cancer
49. Prostate brachytherapy: Treatment strategies
50. Adjuvant and neoadjuvant hormonal therapy for prostate cancer
51. Charge and length of hospital stay analysis of radical retropubic prostatectomy and transperineal prostate brachytherapy
52. Anatomic radical prostatectomy: Evolution of the surgical technique
53. Impotence following radical prostatectomy: Insight into etiology and prevention
54. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer
55. A review of studies of hormonal adjuvant therapy in prostate cancer
56. Adjuvant antiandrogenic treatment after radical prostatectomy in stage C prostate cancer - Preliminary results of a randomized controlled trial
57. Das Lymphknoten-positive Prostatakarzinom. Ein Fall fur die radikale Prostatektomie
58. Bicalutamide (Casodex®) early prostate cancer programme - Final demographic data from over 8000 randomised patients
59. Comorbidity in prostate cancer
60. PSA-Anstieg nach radikaler Prostatektomie
61. Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment